OncoGenex Presents Additional Phase 3 SYNERGY Analyses Showing Custirsen Significantly Reduced Serum Clusterin Levels in Metastatic Prostate Cancer Patients; Low Levels Correlate with Improved Survival in Those at Increased Risk for Poor Outcomes

BOTHELL, Wash. and VANCOUVER, British Columbia, Sept. 28, 2015 -- OncoGenex Pharmaceuticals, Inc. (NASDAQ:OGXI - News) announced today results from additional exploratory analyses of the Phase 3 SYNERGY trial demonstrating that custirsen treatment significantly lowered serum clusterin (sCLU) levels from baseline in men with metastatic castrate-resistant prostate cancer (mCRPC). In addition, these data presented at the 2015 European Cancer Congress (ECC 2015) in Vienna showed that sCLU reductions after custirsen treatment resulted in higher two-year survival rates in patients who were at increased risk for poor outcomes. Of those patients with lower sCLU levels, the data also showed a correlation to an overall survival benefit for custirsen-treated patients who were at increased risk for poor outcomes.

Published: 28 September 2015
Written by Editor
Nasdaq   Up on News   Project Update  
Read more: OncoGenex Pharmaceuticals Inc ( OGXI )

Bellerophon Therapeutics Announces Positive Data From Interim Analysis of Phase 2 Long-Term Extension Study of INOpulse(R) for Treatment of Pulmonary Arterial Hypertension

Conference Call/Webcast to Be Held September 25, 2015 at 9:00am ET ---- Interim Data Reinforces Earlier Phase 2 Data and Indicates Sustainability of Benefits for PAH Patients ---- FDA Issues a Special Protocol Assessment (SPA) for Phase 3 PAH Program

HAMPTON, N.J., Sept. 24, 2015 -- Bellerophon Therapeutics, Inc. (BLPH), a clinical-stage biotherapeutics company, today announced positive data from an interim analysis of the Company's Phase 2 long-term extension study of INOpulse for the treatment of Pulmonary Arterial Hypertension (PAH) (Part 2 of the Company's Phase 2 trial). The data reinforce the results from Part 1 of the Phase 2 trial and indicate a sustainability of benefit to PAH patients who received INOpulse therapy. Bellerophon also reported today that the U.S. Food and Drug Administration (FDA) has issued a Special Protocol Assessment (SPA) for the Company's Phase 3 PAH program for INOpulse, which will include two confirmatory clinical trials, undertaken either sequentially or in parallel, with the first patient expected to be enrolled later this year. A conference call to discuss today's news will be held tomorrow, Friday, September 25, 2015 at 9:00am ET. Details on the conference call are provided below.

Published: 25 September 2015
Written by Editor
Nasdaq   Up on News   Project Update  
Read more: Bellerophon Therapeutics Inc ( BLPH )

Resverlogix Announces the commencement of an Orphan Disease Program specific for Complement Mediated Diseases

Apabetalone (RVX-208) to be tested in a proof-of-concept pilot trial in a complement mediated disease Paroxysmal Nocturnal Hemoglobinuria (PNH) in 2016

CALGARY, Sept. 24, 2015 Resverlogix Corp. ("Resverlogix" or the "Company") (TSX:RVX.TO ) announced today the commencement of an Orphan Disease Program specific for Complement Mediated Diseases. New data generated by Resverlogix has demonstrated that BET inhibition by apabetalone (RVX-208) has effects on multiple biological pathways that underlie disease pathology. Specifically, apabetalone (RVX-208) has been shown to modulate the complement and coagulation pathways, known to play roles in cardiovascular disease and a variety of orphan indications. Based on these findings, Resverlogix plans to pursue a pilot proof-of-concept trial in complement mediated diseases, with the first clinical trial in Paroxysmal Nocturnal Hemoglobinuria (PNH).

Published: 24 September 2015
Written by Editor
TSX   Up on News   Project Update  
Read more: Resverlogix Corp ( RVX )

Capnia Announces Publication of CoSense(R) Clinical Data in the Journal Neonatology

Study Demonstrates Superiority of CoSense in Detecting Hemolysis and Reducing Jaundice-Related Readmissions

REDWOOD CITY, Calif., Sept. 24, 2015 -- Capnia, Inc. (CAPN), focused on the development of novel products based on its proprietary technologies for precision metering of gas flow, today announced a paper, titled "Measuring End-Tidal Carbon Monoxide of Jaundiced Neonates in the Birth Hospital to Identify Those with Hemolysis," has been published online in Neonatology (2016;109:1-5 [DOI:10.1159/000438482]). This peer-reviewed paper, which is expected to appear in the January 2016 print issue, discusses recent clinical research demonstrating the superiority of CoSense(R) End-Tidal Carbon Monoxide (ETCO) Monitor at detecting hemolysis in jaundiced newborns.

Published: 24 September 2015
Written by Editor
Nasdaq   Up on News   Project Update  
Read more: Capnia Inc ( CAPN )

Arrowhead Reports Peak Reduction in HBsAg of Up to 99% (1.9 log) After a Single Dose with Hepatitis B Candidate ARC-520 in Treatment Naïve Cohort of Phase 2a Study

- Single-dose Reductions in HBeAg of up to 98% (1.7 log) also achieved
- Multi-dose studies in chimpanzees showed peak reduction in HBsAg of up to 99.8% (2.7 log)
- Company hosts an analyst and investor day today to discuss results

PASADENA, Calif.-- Arrowhead Research Corporation (ARWR), a biopharmaceutical company developing targeted RNAi therapeutics, is hosting an analyst day today in New York, with a presentation starting at 11:00 a.m. EDT to discuss top-line findings from the Heparc-2001 Phase 2a clinical study of ARC-520, its candidate for the treatment of chronic hepatitis B infection. Additionally, the company will discuss findings from a study of 9 chimpanzees that have been treated monthly with ARC-520 for between 6 and 11 months with a background therapy of nucleotide/nucleoside analog inhibitors (NUCs) tenofovir and/or entecavir.

Published: 24 September 2015
Written by Editor
Nasdaq   Up on News   Project Update  
Read more: Arrowhead Research Corporation ( ARWR )
  1. Oramed Pharmaceuticals Inc ( ORMP )
  2. Concert Pharmaceuticals Inc ( CNCE )
  3. Heron Therapeutics Inc ( HRTX )
  4. Can-Fite BioPharma Ltd ( CANF )
  5. Ampio Pharmaceuticals Inc ( AMPE )